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Summary
The ribosomal P proteins are necessary for GTPase activity during protein synthesis . In addition
to antibodies to the P proteins, sera from lupus patients contain anti-rRNA activity . To determine
whether lupus antiribosomal sera recognize the region of28S rRNA recently proposed to form
part of the ribosomal GTPase center, anrRNA fragment corresponding to nucleotides (nt) 1922-
2020 was transcribed in vitro and tested for antigenicity. 18 of 24 (75%) lupus sera containing
anti-P antibodies, but only 2 of 24 (8%) lupus sera without anti-P, immunoprecipitated this
rRNA fragment (p < 0.001) . The binding was specific, since no significant differences were
observed between anti-P positive and negative lupus sera in binding to theRNA fragment transcribed
in the antisense orientation or to a control region ofrRNA . The majority of sera tested protected
a rRNA fragment of approximately 68 nucleotides . To evaluate the fine specificity ofthe anti-28S
antibodies, deletions and site-directed mutations weremade in theRNA fragment . The anti-28S
antisera required nt 1944-1955 for recognition and were remarkably sensitive to destabilizing
as well as nondestabilizing mutations in the stems of the RNA fragments . Detection of anti-
protein and anti-RNA antibodies directed against a functionally related domain on the ribosome,
together with the remarkable specificity of anti-28S antibodies, strongly suggests a direct role
for this region of the ribosome in initiating and/or maintaining antiribosomal autoantibody
production.
A
ntibodies reactive against single (1) and double (2, 3)
stranded RNA have been detected in the sera ofpatients
with systemic lupus erythematosus (SLE) . However, these
autoantibodies did not show specificity for the type or se-
quence ofRNA (1-3) . Previous studies have also suggested
the possible existence of antibodies against ribosomal (r)'
RNA although the specificity of these antibodies were not
characterized (4-7) . In our study ofantiribosomal antibodies,
we detected an RNase-sensitive antigen by counterimmuno-
electrophoresis (8) . Further efforts to characterize the antigen
were, however, unsuccessful due to high background binding
of all sera torRNA (our unpublished observations) . Recently,
Uchiumi et al . (9) identified a SLE serum that contained an-
tibodies against the ribosomal phosphoproteins P0, P1, and
P2 as well as 28S rRNA . This anti-rRNA antibody was se-
quence specific since it bound to a 59 nucleotide fragment
of 28S rRNA but did not bind to other regions of 28S, 18S
rRNA or rRNA (9) . Sequence analysis oftheRNA segment
protected by the antibody revealed that the epitope was lo-
cated between nucleotides 1944-2002 of28S RNA (9) . Since
the P proteins (10-12) and 28S rRNA (9) may form part of
a functional GTPase domain on the large ribosomal subunit,
we investigated the relationship between anti-P and anti-28S
RNA antibodies .
Materials and Methods
Polymerase Chain Reaction Amplification ofSegments of28S DNA .
Two regions of 28S DNA, approximately 100 by in length, were
selected for study. The region 1922 to 2020 (28S-Ag) included the
59 base pair fragment (1944-2002) of28SDNA encoding theRNA
precipitated by the reference serum (9) . Nucleotides 4430 to 4528
(28S-C) was selected as a control test antigen on the basis ofsimilar
size and similar GC content to 28S-Ag (50.5% for 28S-Ag and
48.5% for 28S-C) . The following primer pairs were used to am-
plify the segments of28SDNA : 5'-GCGAATTCAGGTGTTGGT
TGATATAGAC-3' and 5'-GCTCTAGATTTCAGGGCTAGTTG-
ATTCG-3'for 28SAg; 5'-GTGAAGCAGAATTCGCCAAGC-3'
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1 itg of genomic DNA isolated from HeLa cells was amplified
through30 cycles by thePCRusingTaqpolymerase (13) . Following
amplification, the primerswere removedby ultrafiltration through
Ultrafreemembranes (Millipore Corp., Bedford, MA). TheDNA
fragments were restricted with Eco RI and Xba I and subcloned
into the plasmidpGem 3 (Promega,Madison, WI) . All oftheDNA
sequences were verified by dideoxy sequencing .
Transcription .
￿
Plasmids containing either the 28S-Ag or 28S-C
DNAwere linearized by Eco RI or Xba I . Transcription was per-
formed by the method of Melton et al . (14) using either T7 or
SP6 polymerase and [a"P]CTP. Since pGem3 contains SP6 and
T7 promoters in opposite orientations, sense and antisense RNA
were synthesized from the pGem3-28S-Ag construct (Fig . 1) . Fol-
lowing transcription, the plasmids were digested with RNase-free
DNase and theRNAisolated by phenol/chloroform extraction and
ethanol precipitation .
Sera and Immunoprecipitation.
￿
Sera from patients with SLE con-
taining anti-P antibodies have been described in detail elsewhere
(8, 15, 16) . Anti-P levels were quantified by ELISA using a recom-
binant humanP2 fusion protein (rHuP2) as antigen (17) . Sera from
patients with other multisystem autoimmune diseases (Sjogren's
syndrome, polymyositis, and scleroderma) as well as normal healthy
controls have also been described (18) .
A 10% (v/v) suspension ofSepharose-proteinA (Pharmacia Fine
Chemicals, Piscataway, NJ) was incubated with 5 p,l oftest serum
for 30 min at room temperature. The beads were centrifuged,
washed with buffer A (20mM Tris, pH 7.6, 100 mM KCI, and
5MM MgCl2) and then incubated with the in vitro transcribed,
'2P-labeled 28S rRNA fragments for 45 min at 4°C. 10 jig of yeast
tRNA (Sigma Chemical Co ., St . Louis, MO) was added to the
reaction to minimize degradation of the 32P-labeled RNA. The
beads were washed three times with buffer A and then counted
in liquid scintillation counter. Values greater than 3 SDs above the
mean of 10 normal controls were considered positive . In some cases,
the immunoprecipitated RNA was extracted from the protein A
beads and analyzed on a 10% polyacrylamide gel containing 7M
urea, 90 mM Tris, 90 mM borate and 1 mM EDTA, pH 8.6
(7 M urea PAGE) .
RNAProtection.
￿
To determine the size of 28SRNAprotected
by anti-28S antibodies, IgG fractions were incubated with "P-
labeled RNA synthesized by in vitro transcription in the presence
of 2wg oftRNA for 20 min at 30°C (9) . 2U of RNaseT1(Phar-
macia Fine Chemicals) were added to the reaction and incubation
continued for an additional 15-30min. Immunoprecipitation was
performed as described above and the RNA fragments detected
by 7 M urea PAGE and autoradiography. The sizes of the major
fragments protected by the antibodies were determined by com-
parison with the mobility of RNA fragments of known size .
Results
Anti-P Sera Immunoprecipitate 28SAg rRNA .
￿
The amount
of radiolabeled 28S-AgrRNA precipitated by SLE sera posi-
tive (+) or negative (-) for anti-P antibodies is shown in
Fig . 2, panelAg . 18 of 24 (75%) anti-P positive sera precipi-
tated the 28S-Ag rRNA compared to only 2 of 24 (8%)
anti-P negative SLE controls (Yates XZ = 19 .3, p< 0.001) .
None of thenormal controls (Fig. 2, Ag) andonly 1/15 (7%)
sera obtained from patients with other autoimmune diseases
precipitated the 28S-Ag rRNA (not shown) .
To determine whether lupus sera containing anti-P anti-
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￿
Schematic diagram of the construction of plasmids for tran-
scription . Following amplification of by 1922-2020 (28S-Ag) and 4430-
4528 (28S-C) of28SDNAby PCR, the DNA fragments were subcloned
into pGem3 and transcribed by SP6 or T7 polymerase. The transcribed
RNAs were used as test antigens for immunoprecipitation .
bodies bound specifically to the 28S-Ag fragment, the com-
plementary strand of 28S-AgDNA was transcribed to pro-
duce the 28S antisense (AS) rRNA . In addition, a control
region of 28S DNA was transcribed to produce the rRNA
fragment, 28S-C (Fig. 1) . TheseDNA fragments were tran-
scribedwith similar efficiency to 28S-Ag andwere of theap-
a
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Immunoprecipitation of 28S-Ag (Ag), antisense (AS), and
control (C) fragmentsof 28S-rRNA . TheRNAfragments were transcribed
in vitro in the presence of [tx-32p]CTP and incubated with IgG-bound
to Sepharose proteinA beads. The results are expressed as the amount
of radiolabeled RNA precipitated . The horizontal dashed lines represent
the mean + 3SD ofradiolabeled RNA precipitated by the normal control
sera .propriate sizewhen analyzedon a denaturing polyacrylamide
gel (not shown) . 10 normal sera and 10 randomly selected
sera from the anti-P (+) and anti-P (-) groups were tested
for binding to these RNAs. As shown in Fig. 2, panels AS
and C, only a minority of lupus sera bound to these rRNA
fragments and there were no significant differences between
anti-P (+) and anti-P (-) sera. Preincubation of IgG frac-
tions obtained from anti-28S-Ag sera with 5 jLg of Esche-
richia coli rRNA either had no effect, or increased the amount
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Figure 3 .
￿
Longitudinal studies of anti-28S and anti-P levels in patients
with lupus psychosis. Stored serum samples were tested for anti-28S-Ag
(O) by immunoprecipitation and for anti-P (" ) by ELISA using a recom-
binant human P2 fusion protein (17) . A, B, and C represent studies per-
formed on three different SLE patients.
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of 28S-Ag rRNA precipitated (presumably by preventing
nonspecific adsorption or degradation of the labeled RNA) .
Relationship betureen Anti-P and Anti-28SAg Antibodies. To
ensure that quantitative differences in anti-28S-Ag levels could
be detected within the range studied, a standard curve was
constructed with serial two-fold dilutions of the highest titer
anti-28S-Ag serum . A sigmoid curve was obtained indicating
that the anti-28SAg levels could be quantified by theimmu-
noprecipitation assay (not shown) . We then compared anti-
28S-Ag and anti-P levels in the same 24 SLE anti-P (+) sera .
There was no correlation between the levels of these two an-
tibodies (r = 0.15, p > 0.5) .
Patients with certain neuropsychiatric forms ofSLE show
changes in serum anti-P levels which parallel disease activity
(16, 19) . To determine whether anti-P and anti-28S-Ag levels
fluctuated in parallel, the levels of these two antibodies were
compared in sera obtained from three patients with lupus
psychosis. As shown in Fig . 3, only one of the three sera
(C) demonstrated parallel changes in anti-P and anti-28S-Ag
levels. Since the antibody profile shown inA was compatible
with an idiotype/anti-idiotype mechanism, a mixing experi-
ment was performed . Equal volumes ofserum from the first
and fourth bleeds were mixed and tested for anti-P and anti-
28S activity. No decrease of either antibody activity, other
than that accounted for by dilution, was observed.
Nucleotide Sequence Comparisons.
￿
It was previously shown
that the epitope on human 28S rRNA was identical to nucleo-
tides 1767-1825 of mouse 28SrRNA (9) . To further evaluate
the degree of conservation of the epitope, the 59by sequence
ofhuman 28S rRNA 1944-2002, as well as approximately
175 by flanking this sequence were compared with theDNA
sequences ofthe genes encoding yeast (Saccharom),res cerevisiae)
25S rRNA (20) and E. coli 23S rRNA (21) . Comparisons
were made by the method of Wilbur andLipman (22) using
the DNASTAR program Align . As shown in Fig. 4, there
was a striking similarity between thehuman and yeastrRNA
in the region of epitope (97% similarity and no gaps) . For
comparison, the flanking sequences showed 53-77% similarity
with 7 gaps (not shown) . Although the similarity between
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Nucleotide sequence similarities between the 28S-Ag epitope
(nucleotides 1944-2002) of human (Hu) 28S (42) and the corresponding
regions of Yeast 25S (A) and E. coli (Eco) 23S (B) ribosomalRNAs (19,
20) . Nucleotide identity is shown by a colon .
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asthe human 28S and E. coli 23S rRNA was much lower in
the region of the epitope (63%, Fig. 4), the flanking regions
showed only53-56% similarity with large gaps to maximize
homology. To determine whether the 28S-Ag epitope con-
tained sequence homology to nonribosomal nucleotide se-
quences, a homology search was performed with the sequences
contained in GenBankR, release 64 . No significant sequence
similarities to foreign bacteria or viral RNAs were observed.
RNA Protection .
￿
To determine whether the boundaries
of the 28S Ag were the same for all anti-28S sera, an anti-
body RNase protection experiment was performed. Seven
sera which exhibited minimal nonspecific binding to the con-
trol RNAs, 28S-C and 28S-AS, were tested . As shown in
a representative experiment (Fig . 5), the smallest fragment
protected was approximately 68 nt (lanes 3-6) . Increasing
the amount of RNase T1 to 20 U resulted in a loss of the
105 nt fragment and accumulation ofthe 68 nt fragment (not
shown) . One of the seven sera (from patient, Pa), protected
two fragments of approximately 50 and 46 nt (lane 2) .
Fine Specficities ofAnti-28S Antibodies.
￿
To further evaluate
the fine specificities of the anti-28S Ag antibodies, changes
in the sequence and conformation of the 28SRNA Ag were
made (Table 1) . These changes are described in the legend
to Fig . 6 and their predicted effects on the secondary struc-
ture ofRNA (23) are shown in Fig. 6, A-E . The deletion
mutant, A, was created by restricting the 28S Ag DNA at
the unique Nco I site (bp 1955) . Mutants B through E, were
created by oligonucleotide synthesis and were ligated into
the Eco RI and Sma I sites ofpGEM 3 . All of the mutants
were verified by dideoxy nucleotide sequencing and the sizes
of the labeledRNA transcripts evaluated by 7M urea PAGE
(not shown) .
To determine whether anti-28S sera would bind to shorter
fragments of the 28S AgRNA, immunoprecipitation ofmu-
tantA was performed with the 7 anti-28S sera described above .
As shown in Table 1, deletion of the twelve most 5' nucleo-
tides resulted in almost a 90% decrease in binding when com-
pared to the reference 28S Ag. When the same sera were tested
for binding to mutant B, which lacked only the 3 most 3'
510
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￿
RNA protection by anti-28S IgG. 32P-labeled 28S AgrRNA
was incubated with IgG obtained from five patients with anti-28S anti-
bodies (lanes 2-6) or a normal control (lane 7) . 2U of RNase T1 was
added to the reaction and the protectedRNA isolatedby proteinAimmu-
noprecipitation and phenol/chloroform extraction.The protected fragments
were analyzed on a 7 M urea 10% polyacrylamide gel. Lane 1 contains
the 28S Ag without exposure to IgG or RNase T1 . The estimated size
(nt) of the RNA fragments are shown on the left .
nucleotides, 5/7 sera showed similar recognition of the 28S
Ag and mutant B whereas 2 sera immunoprecipitated only
2% (serum pa) and 43% as much RNA compared to the
28S Ag. Further studies on the effect of site directed muta-
genesis were therefore performed with the 5 sera that bound
to mutant B RNA . The 8 nucleotide substitutions of mu-
tant C were designed to destabilize the secondary structure
The positions of the changes and their predicted effect on the secondary structure of 28S RNA are shown in Fig . 6 .
t The values for each mutant were calculated from (cpm mutant RNA precipitated/cpm 28S Ag RNA precipitated) x 100 . The mean (and range)
of 7 test sera are shown for mutantsA and B. Only 5 sera were studied for mutants C-E since 2 sera demonstrated low binding to mutant B.
Table 1 . Recognition of 28S RNA Ag Mutants by Anti-28S rRNA Sera
Predicted' change in
Mutant Change" Length secondary structure % Immunoprecipitatedt
nt
A A1944-1955 47 Yes 11 (3-25)
B A2000-2002 56 No 75 (2-125)
C 8 substitutions 56 Yes 9 (2-14)
D 2 substitutions 56 Yes 10 (3-16)
E 4 substitutions 56 No 22 (8-39)A
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Deletions and site-directed mutations of the 28S Ag RNA.
(Top) predicted secondary structure of human 28S rRNA nt 1943-2002.
(Bottom) predicted secondary structures ofthe 28S Ag RNA mutants. Mu-
tation A was produced by the deletion ofnt 1944-1955. Mutants B-E were
produced by oligonucleotide synthesis and all contained a deletion of the
three 3' terminal nucleotides (nt 2,000-2,002) of 28S Ag. Mutants C-E
contained additional site-directed changes at the nucleotide numbers indi-
cated: mutant C, 1944 (C-+G), 1946 (G-A), 1949 (CyG), 1950 (G-+A),
1955 (C-"G), 1956 (C-"T), 1979 (G-+A) and 1981 (GyA); mutant D,
1955 (C-+G) and 1956 (CST); mutant E, 1954 (G-C), 1956 (CMG),
1966 (GEC) and 1971 (C-G). The secondary structures of the RNA
fragments were predicted by the FOLD program (23). The helices are la-
beled 36-38 according to the secondary structure proposed for human 28S
RNA (37).
of 28S RNA by preventing base pairing ofa113 stems, 36-3$
(Fig. 6 G). As shown in Table 1, antibody binding to this
RNA fragment was minimal. To determine the effect of
destabilization of a single stem, only 2 nucleotide substitu-
tions were introduced into stem 37 of mutant D (Fig. 6 D).
Despite the minimal sequence changes and predicted altera-
tion in secondary structure, limited antibody recognition of
this fragment was observed (Table 1). Since all previous alter-
ations in the RNA sequence (except B) were also predicted
to have effects on the secondary structure of 28S RNA,
reciprocal changes in two G-C pairs were made in stem 37
of the 2$S Ag so as not to disrupt base pairing (Fig. 6 E).
Antibody recognition of this structure was also poor (Table
1). Although mutants were constructed with substitutions
in the loops of the 28S Ag, recombinant plasmids could not
be isolated from E. coli for reasons which are not understood.
Finally, to determine whether anti-28S antibodies could
distinguish between ribo- and deoxyribo nucleic acids with
the same predicted secondary structure, mutant B oligonu-
cleotides (sense and anti-sense strands) were end labeled with
[ ,y-32p]-ATP and T4 polynucleotide kinase. Immunoprecip-
itation was performed with the same 5 sera that bound to
mutant B RNA. No significant differences in binding to sense
and antisense mutant B oligonucleotides were observed. Simi-
larly, there was no correlation between the levels ofbinding
to the sense mutant B oligonucleotide and 28S Ag RNA.
Discussion
The major finding in this study is that the majority of
lupus anti-P sera, but <10% of anti-P negative SLE sera or
sera from patients with other autoimmune disorders, con-
tained antibodies that bound to a small fragment of28S RNA
(28S Ag). This binding was specific for 28S Ag since anti-P
sera did not show increased binding to RNA transcribed from
the same 28S DNA fragment in the opposite direction an-
tisense (28S-AS) or to a control RNA fragment (28S-C) of
similar size and GC composition. Furthermore, the binding
of anti-28S-Ag antibodies to the 28S Ag could not be in-
hibited by yeast tRNA or E. coli rRNA. The higher back-
ground binding of all sera to the control segments of human
28S rRNA may explain our previous failure to detect sequence
specific anti-28S antibodies usingthe intact 28S RNA mole-
cule. Although the studies performed here do not exclude
the possibility that anti-P or other lupusantisera bind to ad-
ditional epitopes on 28S RNA, detailed analysis of a single
high titer anti-P and anti-28S serum revealed that the only
RNA epitope that could be identified on either 28 or 18S
rRNA was located between nucleotides 1944-2002 of 28S
rRNA (9).
The E. coli ribosomal proteins, L10, L7/12 (L7 is the
acetylated form of L12), are the prokaryotic homologues of
the eukaryotic phosphoproteins P0, Pl, and P2. Although
the exact mechanism is not known, the presence ofthe L7/L12
protein is required for the interaction of elongation factors
with the ribosome and for subsequent GTP hydrolysis
(reviewed in reference 24). A role for 23S rRNA in GTPase
activity was also suggested by inhibition of GTP hydrolysis
by the antibiotic, thiostrepton (25). The binding site for thio-
strepton has been localized to nucleotides 1055-1081 on E.
coli 23S rRNA (26). Thus, both the L7/L12 protein and a
specific region of 23S may constitute the rRNA functional
domain responsible for elongation factor binding and GTP
hydrolysis on the E. coli ribosome. The epitope on 28S RNA
recognizedby SLE antisera is highly conserved in eukaryotic
organisms (97% sequence identity with yeast rRNA) and
shares 62% sequence identity with nucleotides 1051-1110 of
E. coli 23S rRNA (Fig. 6). Since both anti-P antibodies (12,
27) and the prototype anti-28S Ag antibody (9) inhibited
elongation factor binding and GTPase activity, it seems likely
that the P proteins and nucleotides 1944-2002 of 28S rRNA
constitute a similar functional domain to that observed on
E. coli ribosomes. The properties of the 28S-Ag epitope viz.
sequence conservation and participation in an active func-
tional domain are common to most other epitopes mapped
on SLE autoantigens (28).
Case reports of antibodies reactive against individual tRNAs
(29, 30) and Ul RNA (31) have been described. It was sug-
gested that these anti-RNA autoantibodies arise through an
idiotype/antiidiotype mechanism since the patients' sera also
contained antibodies reactive against the proteins to which
the RNAs bind (29, 31). An idiotype/anti-idiotype mecha-
nism is unlikely to explain the presence ofanti-28S Ag anti-
bodies in SLE anti-P sera for the following reasons. The
purified P protein homologues from E. coli (32) and from
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Cyeast (33) do not bind directly to rRNA. We also failed to
detect binding of isolated P1/P2 to the 28S rRNA Ag by
a nitrocellulose filter binding assay or by RNase protection
(our unpublished observations) . Longitudinal analysis ofan-
tibody levels in individual patients with lupus psychosis and
elevations in anti-P levels, showed reciprocal fluctuations of
anti-28S-Ag antibodies in only one out of three patients
studied . Mixing experiments in sera obtained from this pa-
tient did not suggest an idiotype/antiidiotype mechanism .
Considerable evidence supports the idea that autoantibodies
in SLE are antigen-driven (reviewed in reference 34) . Since,
as discussed above, the P proteins and the 28S-AgrRNA ap-
pear to constitute an active functional site, we favor the idea
that SLE patients produce autoantibodies against the pro-
posed GTPase domain on the 60S subunit (9) . Parallel fluctu-
ations in the levels of anti-P and anti-28S autoantibodies in
only one of three patients analyzed longitudinally may be
explained by different patterns of the immune response to
protein versus nucleic acid antigens. Rather than an idio-
type/antiidiotype pattern, the antibody profile shown in Fig .
3, panelA, could reflect an initial response to 28SRNA fol-
lowed by autoantibody production against the P proteins .
Longitudinal studies oflarge numbers of patients will be re-
quired to determine the relationship between anti-P and anti-
28S antibodies.
Although considerable information is now available re-
garding autoantibody recognition of protein antigens (reviewed
in reference 28), little is known about antibody recognition
of specific RNA epitopes. Detailed analysis of a single anti-
U1 RNA antibody (31), revealed that the smallest epitope
recognized was a 40 nt fragment located within the second
stem loop structure . A very recent study of anti-U1 RNA
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